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Tumor necrosis factor a (TNF-a) is a cytokine with infectious agents and has been shown to exert direct
pleiotropic properties that is induced in a variety of antiviral effects.3-5 Although low levels of TNF-a can
pathological situations including viral infections. In this contribute to cell protection, excessive amounts may
work, we analyzed the expression of TNF-a gene in pa- cause cell damage.2,6
tients with chronic hepatitis C. Serum TNF-a levels were The biosynthesis of TNF-a is tightly regulated byfound to be elevated in all chronic hepatitis C patients transcriptional and post-transcriptional mechanisms.1including those cases presenting sustained biochemical
A variety of viruses have been shown to induce theremission of the disease after interferon therapy. Un-
expression of TNF-a in vitro.6-9 The accumulation oftreated patients with chronic hepatitis C showed in-
TNF-a messenger RNA (mRNA) that occur in virus-creased TNF-a messenger RNA (mRNA) levels in the
liver and mononuclear cells as compared with healthy infected cells6,8,9 may result from both increased tran-
controls. After completion of treatment with interferon, scription and stabilization of the transcripts.8 Accumu-
patients experiencing sustained complete response lation of TNF-a mRNA primes the cell for enhanced
showed values of TNF-a mRNA, both in the liver and in release of bioactive TNF-a in response to other in-
peripheral mononuclear cells, within the normal range, ducers such as cytokines, C5a, or bacterial products.1,8significantly lower than patients who did not respond to
TNF-a has been involved in the pathogenesis of ainterferon and than those with complete response who
diversity of liver conditions including viral hepati-relapsed after interferon withdrawal. Pretreatment val-
tis.10-18 Increased production of TNF-a by peripheralues of TNF-amRNA were lower in long-term responders
to interferon than in cases who failed to respond to the blood mononuclear cells (PBMC) has been observed in
treatment. Values of TNF-a mRNA in the liver or in fulminant viral hepatitis,17 in chronic hepatitis B and
mononuclear cells were higher in specimens with posi- in chronic non-A non-B hepatitis.16,18 Recently, raised
tive hepatitis C virus (HCV) RNA than in those samples serum TNF-a levels have been shown in chronic hepati-
where the virus was undetectable. Neither the intensity tis C virus (HCV) infection.19of the liver damage nor the amount of HCV RNA in se-
HCV is a single-stranded RNA virus that infects bothrum or in cells showed correlation with the levels of
the liver and lymphoid cells.20-22 HCV infection has aTNF-a transcripts in peripheral mononuclear cells but
strong tendency to chronicity and constitutes a veryit was found that high TNF-a values were associated
with genotype 1b. In conclusion, there is an enhanced common cause of chronic liver disease in the western
expression of TNF-a in HCV infection. High levels of this world. Thus far, interferon alfa (IFN-a) is the most
cytokine may play a role in the resistance to interferon effective antiviral agent in chronic hepatitis C. How-
therapy. (HEPATOLOGY 1996;23:210-217.) ever, only about 50% of the treated patients respond
to IFN-a therapy with normalization of serum trans-Tumor necrosis factor a (TNF-a) is a cytokine, pro-
aminases, and half of these patients relapse after inter-duced primarily by activated monocytes and lympho-
ruption of the treatment.23cytes, that possesses pleiotropic properties.1,2 It partici-
Little is known about the mechanisms determiningpates in the induction of the immune response to
the severity of the liver damage and the response to
IFN-a in HCV infection. In this paper, we have studied
Abbreviations: TNF-a, tumor necrosis factor a; mRNA, messenger RNA; the levels of TNF-a in serum, TNF-a transcripts in the
PBMC, peripheral blood mononuclear cells; HCV, hepatitis C virus; IFN-a, liver and PBMC in patients with chronic hepatitis Cinterferon alfa; UT, untreated group; SR, sustained response; Rr, response
and the relationship between this cytokine and the re-with relapse; NR, no response; ALT, alanine aminotransferase; ELISA, en-
zyme-linked immunosorbent assay; RT-PCR, reverse transcriptase-polymer- sponse to IFN-a treatment. Our results indicate that
ase chain reaction; cDNA, complementary DNA. the presence of HCV RNA in the liver or in PBMC is
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50 years) and 47 patients with chronic hepatitis C (27 male dles (Baxter, Deerfield, IL). One third of the specimen was
and 20 female; age range, 21 to 75 years). This group of immediately frozen in liquid nitrogen and stored at 0807C
patients included 16 untreated patients and 31 patients who until the extraction of RNA, and the remaining was used for
were studied after completion of treatment with IFN-a (3 histological study.
MU daily for 2 months and 3 MU 3 times a week for 8 to 10 Analysis of Serum TNF-a Levels. To analyze the serum con-
months); of these, 15 did not respond to the therapy and 16 centration of TNF-a we used an ELISA (Cytoscreen; Bio-
exhibited sustained biochemical remission of the disease for source International, Camarillo, CA) using specific anti-hu-
more than 6 months after stopping IFN-a administration. man TNF-a antibodies. The assay was performed following
In addition we analyzed TNF-a mRNA levels in 71 PBMC the instructions of the manufacturers. The sensitivity limit
samples from 61 patients with chronic hepatitis C (44 male of the assay was 1 pg/mL.
and 17 female; age range, 21 to 72 years) and 17 healthy Analysis of TNF-amRNA Levels. To analyze TNF-a mRNA
controls (11 male and 6 female; age range, 25 to 38 years). levels we used a procedure based on the reverse transcrip-
Liver biopsy results showed chronic active hepatitis in all of tion–polymerase chain reaction (RT-PCR). Either PBMC or
them, and cirrhosis was present in 4 cases. Histological activ- liver total RNA (0.75 mg) was reverse-transcribed (60 minutes
ity index in liver samples was determined according to Kno- at 377C) with 250 U of M-MuLV reverse transcriptase (BRL,
dell’s scoring system.24 Twenty patients had not received Gaithersburg, MD) in 25 mL volume of 51 RT buffer (0.25
treatment (untreated group [UT]), and 36 were studied at mol/L Tris-HCl pH 8.3, 0.375 mol/L KCl, 15 mmol/L MgCl2),
the end of 10 to 12 months of IFN-a therapy. These patients supplemented with 5 mmol/L dithiothreitol, 0.4 mmol/L deox-
were classified according to the response to IFN-a into three ynucleoside triphosphate, ribonuclease inhibitor (30 U), and
groups: sustained response (SR), response with relapse (Rr), random hexamers (250 ng) (Boehringer Mannheim, Mann-
and no response (NR). The SR group (n  12) included all heim, Germany). After heating (957C, 5 min) and quick-chill-
patients with normal alanine aminotransferase (ALT) values ing on ice, 6.7- or 10-mL aliquots of the complementary DNA
at the end of therapy with persisting normal values during (cDNA) pool (PBMC or liver respectively) were used for PCR
more than 1 year of follow-up. The NR group (n 11) included amplification in 50 ml of 101 PCR buffer (100 mmol/L Tris-
those patients with elevated ALT levels at the end of therapy. HCl pH 9.3, 500 mmol/L KCl, and 1% Triton X-100) con-
The Rr group (n  13) included all patients with normal ALT taining 0.02 mmol/L deoxynucleoside triphosphate, 50 mCi/
levels at the end of treatment in whom serum ALT levels mL of (a-32P)-deoxyeitidine triphosphate (Amersham, Buck-
increased after interferon withdrawal. In 5 patients, the inghamshire, England), upstream and downstream primers
study was performed on two occasions, before initiation the (40 ng each), 1.5 mmol/L MgCl2 and 2 U of Taq DNA polymer-treatment with IFN-a and at the end of the therapy. All these ase (Promega Corporation, MD). Blank reactions with no
cases showed a sustained response to the treatment. Fifteen RNA were performed in all experiments. PCR amplifications
additional patients showing persistent normal serum ALT of a fragment of b-actin cDNA (using 10 mL of the cDNA
levels after IFN-a therapy were studied 4 to 15 months after pool) were also performed as internal control for each sample.
completion of the treatment (these cases are referred to as the TNF-a cDNA fragments were amplified by 25 or 29 cyclesSR-PT group). Five of these patients had also been studied at (PBMC or liver, respectively) (947C, 597C, and 727C, 1 minutethe end of treatment. each step), and b-actin was amplified by 20 cycles (947C,Samples from liver biopsies from 35 patients (26 males and 557C, and 727C, 1 minute each step) a protocol that avoided9 females; age range, 16 to 71 years) with chronic hepatitis C interference of the plateau effect. Oligonucleotides (5*-3*)(4 with cirrhosis) were studied. This group of patients (of
d(GTCAGATCATCTTCTCGAACC) and d(CAGATAGATGG-whom 14 also had PBMC analyzed) included 10 UT and 25
GCTCATACC) were the upstream and downstream primers,treated subjects in whom liver biopsy specimens were ob-
respectively, used for amplification of 360–base-pair (bp)tained at the end of 12 months of therapy (8 NR, 9 SR, and
fragment (nucleotides 315-673) from human TNF-a cDNA.268 Rr). Normal liver samples were obtained from 6 controls (1
d(TCTACAATGAGCTGCGTGTG) and d(GGTGAGGATCTT-male and 5 female; age range, 41 to 66 years) at laparotomy
CATGAGGT) were the primers used to amplify a 314-bp frag-(in 5 cases because of gallstones and in 1 because of colon
ment from human b-actin cDNA that is located between nu-cancer without apparent liver metastasis).
cleotides 1319-2079 in the reported human b-actin geneAll patients included in the present study were anti-HCV–
sequence.27 After PCR amplifications, 20 mL aliquots of thepositive using enzyme-linked immunosorbent assay (ELISA)
PCR reactions were electrophoresed in 2% agarose gel and(Ortho Diagnostic Systems, second-generation, Raritan, NJ)
bands were visualized by ethidium bromide. Equal size bandsand all of them were or had been (before treatment) serum
were excised and radioactivities were determined. ObtainedHCV RNA positive using the reverse transcription polymer-
values were corrected with background radioactivity fromase chain reaction. Other causes of chronic hepatitis were
blank reactions with no RNA. Finally, values correspondingexcluded.
to TNF-a mRNA were normalized to those of b-actin mRNA.Preparation of PBMC, Serum, and Liver Samples. For iso-
Results are expressed as counts-per-minute (cpm) ratio oflation of PBMC, fresh blood diluted with 1 volume of 0.9%
TNF-a to b-actin. When TNF-a mRNA values were normal-NaCl was overlaid on Lymphopred (Nycomed Pharma AS,
ized to those of b-actin mRNA, it was assumed that b-actinOslo, Norway) with a density of 1.077 g/mL and centrifuged
mRNA was constantly expressed in patients with chronic600g for 30 minutes. The mononuclear cell layer was har-
hepatitis C, both in patients who did not receive treatmentvested at the interphase and washed twice in 0.9% NaCl.
and in those treated with IFN-a. To confirm this, we analyzedPBMC were lysed in 4 mol/L guanidinium thiocyanate and
simultaneously 15 PBMC and 15 liver samples (5 healthystored at 0807C until extraction of total RNA, which was
controls, 5 untreated patients, and 5 treated patients). Noperformed according to the method of Chomczynski and
differences in the cpm values corresponding to b-actin mRNASacchi.25
were observed between the groups. In PBMC samples, cpmTo obtain serum samples, venous blood was collected into
values were 14808.8{ 1411.7, 14238.2{ 1508.8, and 13453.8sterile vacuum blood collection tubes and then centrifuged.
{ 1038.3 in HC, UT, and treated patients, respectively; andSerum was stored at 0707C until used.
Liver specimens were obtained with Tru-Cut biopsy nee- in liver samples, cpm values were 8351.0 { 626.0, 9313.8
m4730$0017 01-18-96 17:06:42 hepal WBS: Hepatology
212 LARREA ET AL. HEPATOLOGY February 1996
chilling on ice. cDNA solution was used for the first PCR in
50 mL of 101 PCR buffer, which also contained 200 ng of the
outer sense primer and 2 U of Taq polymerase (Promega
Corporation, MD). This first amplification was carried out by
35 cycles (947C, 527C, and 727C, 1 minute each step except 7
minutes for final extension at 727C). For the second PCR, 2
mL of the first PCR product was amplified (30 cycles) using
inner primers (200 ng each) and the same conditions as in
the first PCR. After amplification, 15-mL aliquots of the final
PCR reaction were electrophoresed in 2% agarose gel and the
bands were visualized by ethidium bromide staining. The
sequences for oligonucleotide primers were chosen from five
noncoding regions of the HCV genome.28 The primers for
HCV cDNA synthesis and PCR amplification were: the outer
sense, GTATCTCGAGGCGACACTCCACCATAGAT, and outer
antisense, ATACTCGAGGTGCACGGTCTACGAGACCT; and
inner sense, CCACCATAGATCTCTCCCCTGT, and inner
antisense, CACTCTCGAGCACCCTATCAGGCAGT.28a For
HCV RNA analysis in serum, 50 mL aliquots were extracted.
HCV RNA was reverse transcribed with random primers and
PCR was performed using the above conditions.
HCV RNA was quantified by a competitive PCR technique.
Briefly, RNA from 200 mL of serum or 1.5 mg of total RNA
from PBMC was reverse transcribed with random primers in
FIG 1. Relationship between input of total RNA in the reaction
and cpm of the amplification band after RT-PCR of TNF-a and b-
actin gene products in PBMC and in the liver.
{ 1855, and 7899.6 { 744.0 in HC, UT, and treated patients,
respectively.
Validation experiments of PCR assays using known quan-
tities of total RNA (from 0 to 1 mg) were performed (Fig. 1).
The cpm values corresponding to the used amount of either
TNF-a or b-actin mRNA (0.2 and 0.3 mg for TNF-a in PBMC
and liver, respectively, and 0.3 mg for b-actin in both) were
in the linear range of the curve. To analyze whether changes
of TNF-a mRNA levels relative to those of b-actin resulted
in changes of the ratio of TNF-a PCR product cpm/b-actin
PCR product cpm, we performed a RT-PCR with 0.1 or 0.3
mg of total PBMC RNA from a healthy control (for TNF-a or
b-actin, respectively) and added serial dilutions of known
quantities of TNF-a riboprobe (from 25 pg to 0.19 pg). TNF-a
riboprobe was obtained by run-off transcription of a plasmid
which contained a 760-bp insert (nucleotides 156-916) from
the human TNF-a cDNA.26 As shown in Fig. 2, with increas-
ing amounts of TNF-a mRNA used in the reaction, we ob-
tained a progressive increase of the TNF-a/b-actin ratio (the
increase was linear up to 1.56 pg of the TNF-a riboprobe).
The coefficient of interassay variation for TNF-a/b-actin
was 13.58%. The identity of the PCR products from TNF-a
cDNA amplification was further verified, first, by Southern
blot analysis, using a-32P-labelled PstI/BamHI fragment (1.6
kb-long) of TNF-a cDNA26 as hybridization probe and, second,
by digestion with BglII, PvuII and EcoRI. The two former
enzymes yielded the predicted restriction fragments while
EcoRI did not digest the amplified PCR product (no restric-
tion site for this endonuclease is present in the amplified
region).
Detection and Quantification of HCV RNA. The presence
FIG 2. (A) Relationship between the amount of TNF-a riboprobeof HCV RNA in liver and PBMC was studied by RT-PCR
added to RNA extracted from normal PBMC and the ratio TNF-as previously described.20 Briefly, 0.25 mg of total RNA was
a PCR product cpm/b-actin PCR product cpm. (B and C) The gelreverse transcribed with M-MuLV reverse transcriptase (50 photographs show increasing intensity of the TNF-a amplification
U) (BRL, Gaithersburg, MD) in 10-mL volume of 51 RT buffer band (B) but constant intensity of the b-actin amplification band (C),
supplemented with 200 ng of the outer antisense primer. when increasing amounts of a TNF-a riboprobe (0, 0.19, 0.39, 0.78,
cDNA synthesis proceeded for 60 minutes at 377C, and was 1.56, 3.12, 6.25, 12.5, and 25 pg, lines 2 to 10, respectively) are added
to the RNA extracted from normal PBMC. Line 1, molecular weight.stopped by heating at 957C for 5 minutes followed by quick
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second PCR were 5*-labelled with digoxigenine, and hybrid-
ization was detected using an antidigoxigenine peroxidase-
labeled antibody (Boehringer Mannheim).
Statistical Analysis. Results are presented as mean { SE.
The statistical analysis was performed using nonparametric
tests (Kruskal-Wallis and Mann-Whitney U tests). Pearson’s
correlation coefficients were evaluated by Student’s t test.
RESULTS
TNF-a Gene Expression and the Response to Inter-
feron Treatment. Serum TNF-a levels were higher in
untreated patients with chronic hepatitis C (166.28
{ 33.21 pg/mL) and in those who failed to respond to
IFN after 10 to 12 months of treatment (163.05{ 36.72
pg/mL) than in healthy controls (19.28 { 5.20 pg/mL;
P .001). Patients who made a complete and sustained
biochemical response to IFN-a therapy also showed se-FIG 3. Transcriptional expression of TNF-a gene (as a ratio to
rum TNF-a levels (117.14 { 24.46 pg/mL) significantlythat of b-actin) in PBMC in healthy controls (C) and patients with
higher than control values (P .001). Although in thischronic hepatitis C without treatment (UT) or after 10 to 12 months
of interferon alfa treatment. NR, patients with no response to inter- group of patients serum TNF-a tended to be lower than
feron studied at the end of the treatment; Rr, patients with complete in nonresponders to IFN-a, this difference did not at-
response but with post-therapy relapse studied at the end of the tain statistical significance.treatment; SR, patients with complete response without post-therapy
TNF-a mRNA levels in UT, NR, and Rr patients wererelapse (sustained response) studied at the end of the treatment; SR-
PT, patients with sustained response studied 4 to 15 months after higher than in healthy controls both in PBMC (Fig. 3)
completion of interferon treatment. *P  .01 vs. UT or NR or Rr; and in the liver (Fig. 4). In contrast, in SR patients,
**P  .05 vs. SR or SR-PT; ***P  .05 vs. SR. TNF-a mRNA values in PMBC and in liver tissue were
similar to controls and significantly lower than in UT,
NR, and Rr patients. No differences in hepatic and40 mL or 60 mL of volume, respectively. After reverse tran-
PBMC TNF-a mRNA levels were observed among thesescription, 5 mL of cDNA from serum or 10 mL of cDNA from
last three groups of patients. TNF-a gene expressionPBMC was mixed with serial dilutions of a competitor DNA
in PBMC in SR-PT group was similar to that of the SR(6 1 105, 6 1 104 and 6 1 103 molecules for serum, and 3
1 105, 6 1 104, 3 1 104, and 6 1 103 for PBMC) that differed group (Fig. 3).
from the cDNA of interest by a small delection (45 bases). Fifteen patients from the UT group underwent IFN-
This competitor DNA was produced from cloned DNA from a therapy. Of these, 5 experienced sustained response
5* nonconding region of one HCV-infected patient. Samples to the treatment, and 10 did not respond to IFN-a.
were amplified by nested PCR with two sets of primers (5*- Pretreatment levels of TNF-a mRNA in PBMC were
CCTGTGAGGAACTACTGTCT-3* and 5*-CTATCAGGCAGT- significantly higher in the patients who failed to re-ACCACAAG-3* for outer primers; 5*-ACTGTCTTCACGCAG-
spond to IFN-a than in those patients who exhibited aAAAGC-3* and 5*-GACCCAACACTACTCGGCTA-3* for in-
sustained response to the therapy (0.75 { 0.1 vs. 0.28ner primers). For both PCRs, 30 cycles were performed as
follows: denaturation for 15 seconds at 957C, annealing for
12 seconds at 527C, and extension for 20 seconds at 727C with
a final extension for 1 minute at 727C, in a Perkin Elmer
(Norwalk, CT) Gene Amp PCR System 9600. First PCR were
performed in 40-mL mixtures and 2 mL of the first PCR prod-
uct was transferred to the second PCR mixture performed
in 20 mL, and containing 25 mCi/mL of (a-32P)-deoxycitidine
triphosphate. After second PCR amplifications, 15-mL ali-
quots of the PCR reactions were electrophoresed in 2.5%
agarose gel, and bands were visualized by ethidium bromide.
Equal-sized bands from cDNA and competitor DNA were ex-
cised and radioactivities were determined and compared. The
cpm corresponding to competitor DNA was corrected by the
number of citosines in which competitor DNA differs from
the studied cDNA. The copy number of HCV RNA in the
samples is considered equal to the copy number of the com-
petitor when the cpm of the studied cDNA/cpm of the competi-
tor is equal to 1.
HCV Genotypes. Genotyping was performed by means of a
hybridization procedure using specific probes for HCV geno-
types 1a, 1b, 2a, 2b, and 3a, according to Simmonds et al.,29 FIG 4. Transcriptional expression of TNF-a gene (as a ratio to
and the amplified nested PCR product of the HCV core region. that of b-actin) in the liver in patients with chronic hepatitis C. (C)
Probes, primers, and technique were as described by Viazov normal liver. Other initials as in Fig. 2. *P  .005 vs. UT or NR or
Rr; **P  .006 vs. SR.et al.30 with the following modifications: the primers for the
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FIG 5. Pretreatment values of TNF-a mRNA (as a ratio to b-
actin) in PBMC in patients with chronic hepatitis C; SR, patients
who subsequently underwent interferon therapy and experienced a
sustained complete response to the treatment, and NR patients who
failed to respond to the therapy. Shadowed area represents healthy
control values (mean { 2SD).
FIG 6. Levels of TNF-a mRNA (as a ratio to b-actin) in patients
with chronic hepatitis C at the end of 10 to 12 months treatment
with interferon. Patients were divided according to their HCV geno-{ 0.06, P  .01) (Fig. 5). These data suggest that high type. NR, no response to interferon; Rr, complete response with post-
pretreatment TNF-a mRNA values are associated with therapy relapse; SR, sustained complete response.
lack of response to IFN-a.
In five patients who presented sustained response to
IFN-a, TNF-a mRNA levels were determined in PBMC cases and in 19 of 20 PBMC samples. In patients whobefore and at the end of the therapy. Of these cases, in had received IFN-a treatment, HCV RNA was presentone there was a substantial reduction in the levels of in 19 of 51 PBMC samples and in 16 of 25 liver biopsythe cytokine transcripts (from 0.44 before treatment to specimens (see Table 1).0.09 after treatment), in two there was a slight de- As shown in Fig. 7, when the patients studied at thecrease (from 0.39 to 0.30 and from 0.13 to 0.06), and end of 10 to 12 months of treatment with IFN-a werein the remaining two there was a slight increase (from divided according to the presence or absence of HCV0.31 to 0.41 and from 0.13 to 0.24). Overall, IFN-a RNA in the liver or in PBMC, it was shown that TNF-treatment did not induce significant changes in TNF-
a mRNA values in the corresponding tissue were
a mRNA values in this group of patients who already higher in those cases with detectable HCV RNA thanpresented low basal levels of TNF-a transcripts. in cases where HCV RNA was negative (0.70 { 0.10HCV genotyping was performed in 18 UT patients vs. 0.28 { 0.03, P .002 in PBMC; 0.79 { 0.06 vs. 0.49and in 36 patients studied at the end of IFN-a therapy. { 0.09, P  .05 in liver).In UT patients, genotype 1b was observed in 13, geno-
type 1a in 2 patients and genotype 3 in 3 patients.
Among patients studied at the end of IFN-a therapy,
TABLE 1. Presence of HCV RNA in Liver Samples and ingenotype 1b was found in all NR subjects, in 11 of 13
PBMC From Patients With Chronic Hepatitis CRr cases and in 8 of 12 SR patients; genotype 3 was
Liver PBMCfound in 4 patients (2 Rr and 2 SR), and genotype 1a
in 2 patients (both SR). When we analyzed the relation-
UT 9/9† 19/20ship between the transcriptional expression of TNF-a
NR* 7/8 9/11in PBMC and the HCV genotype of the patient, we Rr* 7/8 9/13
observed that in both untreated patients (Fig. 5) and SR* 2/9 0/12
in the patients studied after IFN-a treatment (Fig. 6), SR-PT — 1/15
high values of TNF-a transcripts (0.60) were associ-
Abbreviations: UT, untreated patients; NR, patients who did notated with genotype 1b. Also, as shown in Figs. 5 and
respond to the treatment; Rr, patients with complete response but6, the majority of patients who failed to respond to IFN-
with posttreatment relapse; SR, patients with complete response anda showed genotype 1b.
sustained normal aminotransferases during posttherapy follow-up;
TNF-a Gene Expression and the Presence of HCV SR-PT, patients with sustained response studied 4 to 12 months
RNA. We studied the relationship between TNF-a gene after completion of interferon treatment.
expression and the presence of HCV RNA in the liver * Patients at the end of 10 to 12 months of treatment with inter-
and in PBMC. As indicated in Table 1, in untreated feron alfa.
† Number of positive cases/number of cases studied.patients, HCV RNA was detected in liver tissue in all
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logical activity index, 11.4) (0.44 { 0.1 vs. 0.66 { 0.1;
NS).
Considering all patients, no correlation was observed
between TNF-a mRNA values, measured in the liver
or in PBMC and the levels of serum aminotransferases.
Also, there was no correlation between TNF-a mRNA
values and the Knodell’s score of the liver biopsy re-
sults (similar results were obtained when total Knodell
index or when only inflammatory parameters were con-
sidered).
DISCUSSION
This study and previous reports20,21 show that HCV
can be observed not only in serum and hepatocytes but
also in lymphoid cells, and our results indicate that
HCV infection is associated with increased transcrip-
tional expression of the TNF-a gene, in both the liver
and PBMC and with high serum levels of TNF-a.
Induction of TNF-a gene by viruses has been shown
to occur in a variety of in vitro models,4,6-9,31 as well as
in diverse viral diseases, including HBV- and HCV-
induced hepatitis.11,16-19,32 It has been recently shown
FIG 7. Levels of TNF-a mRNA (as a ratio to b-actin) in PBMC that production of TNF-a in the liver takes place not
and in the liver in patients with chronic hepatitis C at the end of only in nonparenchymal cells but also in hepatocytes.33
10 to 12 months treatment with interferon. Patients were divided The precise stimulus responsible for enhanced TNF-aaccording to the presence (HCV/) or absence (HCV0) of HCV RNA
gene expression in chronic viral hepatitis has not beenin the corresponding specimen.
defined. Although TNF-a may be generated during the
inflammatory reaction that follows the immune recog-
nition of viral antigens, the mere intracellular presence
To evaluate whether TNF-a gene expression might of viral compounds may also stimulate TNF-a gene ex-
be related to the quantity of the viral load, we quanti- pression as a built-in defense program of the cell to
fied HCV RNA in serum in all of the 20 untreated activate neighboring leukocytes or macrophages7 or to
patients and in PBMC in 15 of these subjects using undergo apoptosis,34 thus limiting the spread of infec-
a competitive PCR method. We found no correlation tion.
between the levels of TNF-a mRNA in PBMC and the In this study, we did not find a correlation between
levels of HCV RNA in serum (P  .74) or in PBMC (P the activity of the liver disease and the level of TNF-a
 .84). Although the levels of HCV RNA before treat- gene expression in the liver or PBMC. However, we
ment tended to be higher in NR than in SR patients, observed a relationship between the presence of HCV
the differences were not significant either in serum (3.4 RNA in the cells and the values of TNF-a transcripts.
1 107 copies/mL vs. 5.41 106 copies/mL; not significant Thus, in UT patients TNF-a mRNA levels were shown
[NS]) or in PBMC (9.6 1 104 copies/mg RNA vs. 6.3 to be increased in the liver and in PBMC, and HCV
1 104 copies/mg RNA; NS). RNA was detectable in both sites; whereas in SR pa-
TNF-a Gene Expression and Liver Damage. TNF-a tients, HCV RNA was absent from both the liver and
transcripts in the liver and in PBMC were similar in PBMC in the majority of cases, and TNF-a mRNA val-
patients with and without cirrhosis (0.75 { 0.1 vs. 0.67 ues were comparable to those observed in normal sub-
{ 0.04, and 0.31 { 0.08 vs. 0.53 { 0.06, NS). We com- jects. On the other hand, in NR subjects and in Rr
pared TNF-a mRNA values in liver samples from the patients, HCV RNA persists in the liver and lymphoid
eight Rr patients (all of them with low activity of the cells at the end of the treatment in most cases, and
liver lesion at the end of the treatment) with those this is associated with an enhanced transcriptional ex-
found in 10 untreated patients with high activity index pression of TNF-a in these two groups of patients.
in the liver biopsy specimens. In the former group the The idea that the transcriptional expression of TNF-
Knodell index in liver specimens obtained at the end a is related more to the intracellular presence of the
of treatment was significantly lower than in the latter virus than to the activity of the liver disease is sup-
group of patients (6.75 { 0.8 vs. 11.5 { 0.9; P  .005), ported by the following observations. At the end of IFN-
but hepatic TNF-a mRNA values were similar in both a therapy, serum aminotransferase levels were equally
groups (0.79 { 0.08 vs. 0.68 { 0.04; NS). Furthermore, normal in Rr and SR patients, whereas TNF-a levels
among untreated patients, there were five subjects in PBMC and in the liver were significantly increased
with minimal changes in the liver biopsy results (mean in the former group. The main difference between these
histological activity index, 4); in these cases, TNF-a two groups of patients was viral persistence in patients
mRNA levels in PBMC were similar to those observed who eventually relapsed. On the other hand, UT pa-
tients showed a more active liver lesion (as estimatedin untreated patients with active disease (mean histo-
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by serum transaminase levels and histological activity tients with chronic hepatitis C previously resistant to
IFN-a alone.44 From our data it could be speculatedindex) than Rr patients, but both groups of patients
had similarly increased TNF-a mRNA levels, and in that high TNF-a levels produce oxidative stress,
which in turn stimulates TNF-a synthesis and causesboth, HCV RNA was detectable in liver tissue and
lymphoid cells. IFN-a resistance. This would explain the higher TNF-
a values observed in patients insensitive to IFN-aAlthough the presence of the virus appears to deter-
mine an enhanced TNF-a gene expression, neither the treatment. Further studies are needed to determine
whether pretreatment analysis of TNF-a gene expres-level of viremia nor the quantity of HCV RNA in PBMC
were shown to be related to the amount of TNF-a tran- sion can be useful to predict the response to IFN-a in
chronic hepatitis C.scripts. Interestingly, the serum concentration of TNF-
a was observed to be increased not only in untreated
Acknowledgment: We thank C. Asensio for excel-patients and in patients who did not respond to IFN-
lent technical assistance.a treatment but also (although to a lesser extent) in
those who exhibited sustained complete response to the
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